What are the dosing and administration recommendations for Toujeo (insulin glargine‑300) in adults with type 1 or type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Toujeo Dosing and Administration

Administer Toujeo (insulin glargine 300 U/mL) subcutaneously once daily at the same time each day into the abdomen, thigh, or deltoid, with individualized dosing based on metabolic needs and glucose monitoring. 1

Administration Guidelines

Route and Timing

  • Inject subcutaneously once daily at any time during the day, but maintain consistency with the same time each day 1
  • Rotate injection sites (abdomen, thigh, deltoid) to reduce risk of lipodystrophy and localized cutaneous amyloidosis 1
  • Do not dilute or mix with any other insulin or solution 1
  • Available only in prefilled pens (1.5 mL SoloStar and 3 mL Max SoloStar) to minimize dosing errors 1

Starting Dose in Type 2 Diabetes

  • Initial dose: 0.2 units/kg body weight for insulin-naïve patients 2
  • This aligns with the FDA-approved approach of individualizing based on metabolic needs 1

Dose Titration

Use structured titration algorithms targeting fasting blood glucose (FBG):

  • Target FBG range: 90-130 mg/dL for most patients 2
  • Alternative target: 110-150 mg/dL for patients requiring less aggressive control 2
  • Titrate over weeks to months based on FBG monitoring 2
  • In simulation studies, 93% of patients achieved target FBG within 3 months using algorithmic titration 2

Critical Dosing Considerations

Concentration Differences

Toujeo (U-300) is NOT bioequivalent to Lantus (U-100) - this is a critical safety point:

  • U-300 glargine has a longer duration of action (>24 hours) and flatter pharmacokinetic profile than U-100 3, 4
  • Higher daily doses required with Gla-300 compared to Gla-100 to achieve equivalent glycemic control 4, 5
  • When switching from U-100 to U-300, expect to need dose adjustments upward 4

Monitoring Requirements

  • Closely monitor glucose when initiating and during the first several weeks 1
  • Increase monitoring frequency with any changes to insulin regimen, concomitant medications, meal patterns, or physical activity 1
  • Enhanced monitoring needed in patients with renal/hepatic impairment or hypoglycemia unawareness 1

Safety Profile

Hypoglycemia Risk

  • Lower nocturnal hypoglycemia risk compared to NPH and potentially U-100 glargine, particularly in type 2 diabetes 5
  • In type 1 diabetes, hypoglycemia rates are comparable between U-100 and U-300 formulations 5
  • Minimal hypoglycemia observed in titration studies (3-4% of patients) 2

Common Pitfalls to Avoid

  • Never share pens between patients, even with needle changes 1
  • Check insulin labels before each injection to prevent accidental mix-ups with other insulin products 1
  • Do not use U-100 syringes with concentrated insulins 3
  • Monitor potassium levels in at-risk patients (hypokalemia can be life-threatening) 1

Integration with Other Therapies

Type 2 Diabetes

  • Can be combined with 1-2 oral hypoglycemic agents 6
  • If additional prandial coverage needed, add rapid-acting insulin at largest meal (start with 4 units or 10% of basal dose) 3

Type 1 Diabetes

  • Use as part of basal-bolus regimen with prandial insulin 3
  • The prolonged >24-hour duration ensures full daily coverage with once-daily dosing 7

Contraindications

  • During episodes of hypoglycemia 1
  • Hypersensitivity to insulin glargine or excipients 1
  • Not recommended for diabetic ketoacidosis 1

Drug Interactions

Adjust insulin dosage when using drugs affecting glucose metabolism, including beta-blockers (which may mask hypoglycemia symptoms) 1. Monitor for fluid retention when combining with thiazolidinediones 1.

Related Questions

How do I convert a patient taking Lantus (insulin glargine) 50 units twice daily to Toujeo (insulin glargine‑U300) dosing?
Should the patient receive the scheduled 10 units of insulin glargine after already receiving 16 units and having a blood glucose of approximately 110 mg/dL?
Should the scheduled dose of long‑acting insulin glargine (Lantus) be administered for a patient with a current capillary blood glucose of 94 mg/dL?
Can the basal insulin glargine (Basaglar) dose be increased from 10 units nightly?
Should a 74-year-old male with diabetes be taking Toujeo (insulin glargine) 50 units daily and U‑500 regular insulin 30 units three times daily?
What are the recommended levothyroxine dosing guidelines for treating hypothyroidism in adults, including elderly, patients with cardiac disease, and pregnant women?
Can carvedilol 3.125 mg taken twice daily exacerbate rosacea-associated facial erythema?
At what size of an incidentally discovered ascending aortic aneurysm (4.5 cm on a calcium CT scan) should I become concerned?
What is the approach to differential diagnosis of central nervous system space‑occupying lesions in an HIV‑positive patient with negative serology for toxoplasmosis, tuberculosis, and other common etiologies?
In a 76-year-old female residing in an assisted‑living facility who has persistent pyuria, recent nitrofurantoin therapy, new yellow vaginal discharge and dyspareunia, normal vital signs, normal external genitalia, pale thin vulvovaginal mucosa, and a negative urine culture, what is the next best step in management?
Can ciprofloxacin be used to treat an infected ingrown hair?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.